Product Description
Mechanisms of Action: 5-HT6 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Multiple Sclerosis|Optic Neuritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2008-001999-67 | P2 |
Completed |
Multiple Sclerosis |
2010-03-02 |
|
DRI10566 | P2 |
Completed |
Multiple Sclerosis |
2010-03-01 |
|
ACT10573 | P2 |
Completed |
Multiple Sclerosis|Optic Neuritis |
2009-06-01 |